310 related articles for article (PubMed ID: 31035251)
1. DNA methylation in thyroid cancer.
Zafon C; Gil J; Pérez-González B; Jordà M
Endocr Relat Cancer; 2019 Jul; 26(7):R415-R439. PubMed ID: 31035251
[TBL] [Abstract][Full Text] [Related]
2. Aberrant DNA methylation in melanoma: biomarker and therapeutic opportunities.
Micevic G; Theodosakis N; Bosenberg M
Clin Epigenetics; 2017; 9():34. PubMed ID: 28396701
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of DNMT3A alterations in Middle Eastern papillary thyroid carcinoma.
Siraj AK; Pratheeshkumar P; Parvathareddy SK; Bu R; Masoodi T; Iqbal K; Al-Rasheed M; Al-Dayel F; Al-Sobhi SS; Alzahrani AS; Al-Dawish M; Al-Kuraya KS
Eur J Cancer; 2019 Aug; 117():133-144. PubMed ID: 31280122
[TBL] [Abstract][Full Text] [Related]
4. DNA methylation profiling of well-differentiated thyroid cancer uncovers markers of recurrence free survival.
Mancikova V; Buj R; Castelblanco E; Inglada-Pérez L; Diez A; de Cubas AA; Curras-Freixes M; Maravall FX; Mauricio D; Matias-Guiu X; Puig-Domingo M; Capel I; Bella MR; Lerma E; Castella E; Reverter JL; Peinado MÁ; Jorda M; Robledo M
Int J Cancer; 2014 Aug; 135(3):598-610. PubMed ID: 24382797
[TBL] [Abstract][Full Text] [Related]
5. PRIMA-1 selectively induces global DNA demethylation in p53 mutant-type thyroid cancer cells.
Qiang W; Jin T; Yang Q; Liu W; Liu S; Ji M; He N; Chen C; Shi B; Hou P
J Biomed Nanotechnol; 2014 Jul; 10(7):1249-58. PubMed ID: 24804545
[TBL] [Abstract][Full Text] [Related]
6. Epigenetics in Medullary Thyroid Cancer: From Pathogenesis to Targeted Therapy.
Vitale G; Dicitore A; Messina E; Sciammarella C; Faggiano A; Colao A
Recent Pat Anticancer Drug Discov; 2016; 11(3):275-82. PubMed ID: 27306881
[TBL] [Abstract][Full Text] [Related]
7. Integrated data analysis reveals potential drivers and pathways disrupted by DNA methylation in papillary thyroid carcinomas.
Beltrami CM; Dos Reis MB; Barros-Filho MC; Marchi FA; Kuasne H; Pinto CAL; Ambatipudi S; Herceg Z; Kowalski LP; Rogatto SR
Clin Epigenetics; 2017; 9():45. PubMed ID: 28469731
[TBL] [Abstract][Full Text] [Related]
8. Loss of DNA methylation is related to increased expression of miR-21 and miR-146b in papillary thyroid carcinoma.
Ortiz IMDP; Barros-Filho MC; Dos Reis MB; Beltrami CM; Marchi FA; Kuasne H; do Canto LM; de Mello JBH; Abildgaard C; Pinto CAL; Kowalski LP; Rogatto SR
Clin Epigenetics; 2018 Nov; 10(1):144. PubMed ID: 30454026
[TBL] [Abstract][Full Text] [Related]
9. Walking pathways with positive feedback loops reveal DNA methylation biomarkers of colorectal cancer.
Kel A; Boyarskikh U; Stegmaier P; Leskov LS; Sokolov AV; Yevshin I; Mandrik N; Stelmashenko D; Koschmann J; Kel-Margoulis O; Krull M; Martínez-Cardús A; Moran S; Esteller M; Kolpakov F; Filipenko M; Wingender E
BMC Bioinformatics; 2019 Apr; 20(Suppl 4):119. PubMed ID: 30999858
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic Alterations and Canonical Pathway Disruption in Papillary Thyroid Cancer: A Genome-wide Methylation Analysis.
White MG; Nagar S; Aschebrook-Kilfoy B; Jasmine F; Kibriya MG; Ahsan H; Angelos P; Kaplan EL; Grogan RH
Ann Surg Oncol; 2016 Jul; 23(7):2302-9. PubMed ID: 26979305
[TBL] [Abstract][Full Text] [Related]
11. The potential of DNA modifications as biomarkers and therapeutic targets in oncology.
Jankowska AM; Millward CL; Caldwell CW
Expert Rev Mol Diagn; 2015; 15(10):1325-37. PubMed ID: 26394702
[TBL] [Abstract][Full Text] [Related]
12. DNA methylation of MAPK signal-inhibiting genes in papillary thyroid carcinoma.
Lee EK; Chung KW; Yang SK; Park MJ; Min HS; Kim SW; Kang HS
Anticancer Res; 2013 Nov; 33(11):4833-9. PubMed ID: 24222120
[TBL] [Abstract][Full Text] [Related]
13. DNA methylation in cancer: a gene silencing mechanism and the clinical potential of its biomarkers.
Fukushige S; Horii A
Tohoku J Exp Med; 2013 Mar; 229(3):173-85. PubMed ID: 23419314
[TBL] [Abstract][Full Text] [Related]
14. Genome-wide DNA methylation profiling and its involved molecular pathways from one individual with thyroid malignant/benign tumor and hyperplasia: A case report.
Cai LL; Liu GY; Tzeng CM
Medicine (Baltimore); 2016 Aug; 95(35):e4695. PubMed ID: 27583899
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in molecular biology of thyroid cancer and their clinical implications.
Xing M
Otolaryngol Clin North Am; 2008 Dec; 41(6):1135-46, ix. PubMed ID: 19040974
[TBL] [Abstract][Full Text] [Related]
16. PAX3 is a novel tumor suppressor by regulating the activities of major signaling pathways and transcription factor FOXO3a in thyroid cancer.
Liu W; Sui F; Liu J; Wang M; Tian S; Ji M; Shi B; Hou P
Oncotarget; 2016 Aug; 7(34):54744-54757. PubMed ID: 27458157
[TBL] [Abstract][Full Text] [Related]
17. DNA methylation signatures identify biologically distinct thyroid cancer subtypes.
Rodríguez-Rodero S; Fernández AF; Fernández-Morera JL; Castro-Santos P; Bayon GF; Ferrero C; Urdinguio RG; Gonzalez-Marquez R; Suarez C; Fernández-Vega I; Fresno Forcelledo MF; Martínez-Camblor P; Mancikova V; Castelblanco E; Perez M; Marrón PI; Mendiola M; Hardisson D; Santisteban P; Riesco-Eizaguirre G; Matías-Guiu X; Carnero A; Robledo M; Delgado-Álvarez E; Menéndez-Torre E; Fraga MF
J Clin Endocrinol Metab; 2013 Jul; 98(7):2811-21. PubMed ID: 23666970
[TBL] [Abstract][Full Text] [Related]
18.
Camargo Barros-Filho M; Barreto Menezes de Lima L; Bisarro Dos Reis M; Bette Homem de Mello J; Moraes Beltrami C; Lopes Pinto CA; Kowalski LP; Rogatto SR
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30884810
[TBL] [Abstract][Full Text] [Related]
19. Disruption of cell-type-specific methylation at the Maspin gene promoter is frequently involved in undifferentiated thyroid cancers.
Ogasawara S; Maesawa C; Yamamoto M; Akiyama Y; Wada K; Fujisawa K; Higuchi T; Tomisawa Y; Sato N; Endo S; Saito K; Masuda T
Oncogene; 2004 Feb; 23(5):1117-24. PubMed ID: 14743202
[TBL] [Abstract][Full Text] [Related]
20. The epigenetic landscape of differentiated thyroid cancer.
Asa SL; Ezzat S
Mol Cell Endocrinol; 2018 Jul; 469():3-10. PubMed ID: 28711609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
